Determinants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012

PLoS One. 2014 May 1;9(5):e96307. doi: 10.1371/journal.pone.0096307. eCollection 2014.

Abstract

Objectives: To investigate the duration of sequential HAART regimens and predictors of first-line regimen discontinuation among HIV-1 vertically infected children and adolescents.

Design: Multicentre survey of antiretroviral-naïve patients enrolled in the HIV-Paediatric Cohor,t CoRISpeS-Madrid Cohort, Spain.

Methods: Patients with a follow-up of ≥ 1 month spent on HAART, with available baseline CD4 count and HIV-viral load (VL) were included. Time spent on sequential HAART regimens was estimated and multivariable regression was used to identify predictors of time to first-line regimen discontinuation.

Results: 104 patients were followed for a median 8 years after starting HAART among 1996-2012; baseline %CD4 was 21.5 (12.3-34.0)and viral load was 5.1 (4.6-5.6) log10 copies/mL. Patients received a mean of 1.9 regimens. Median time on first-line HAART (n = 104) was 64.5 months; second HAART (n = 56) 69.8 months; and third HAART (n = 21) 66.5 months. Eleven (11%) patients were lost to follow-up while on first-line HAART and 54% discontinued (cumulative incidence of 16% and 38% by 1 and 3-year, respectively). The main predictor of first-line regimen discontinuation was suboptimal adherence to antiretrovirals (AHR: 2.60; 95% CI: 1.44-4.70).

Conclusions: Adherence to therapy was the main determinant of the duration of the first-line HAART regimen in children. It is important to identify patients at high risk for non-adherence, such as very young children and adolescents, in provide special care and support to those patients.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antiretroviral Therapy, Highly Active / methods*
  • CD4 Lymphocyte Count
  • Child
  • Child, Preschool
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV-1 / drug effects*
  • Humans
  • Infant
  • Infant, Newborn
  • Lost to Follow-Up
  • Male
  • Patient Compliance
  • Regression Analysis
  • Risk Factors
  • Spain
  • Viral Load / drug effects

Grants and funding

This work was supported by grants provided by the Fondo de Investigación de Sanidad en España (FIS) [grant numbers PI11-00888, PS09/02029, and PI13/02016], Red Española de Investigación en SIDA (RIS) [grant numbers RETIC RD06/0006/0035 RD12-0017-0037; RD06/0006/0021, RD12/0017/0029 and RD09/0076/00103], “Fundación para la Investigación y la Prevención del Sida en España” (FIPSE), Comunidad de Madrid [grant numbers, S-2010/BMD-2351, S-2010/BMD-2332], PENTA and Fundación Eugenio Rodríguez Pascual and grants PTDC/SAU-FAR/115290/2009 and PTDC/SAU-EPI/122400/2010 from Fundação para a Ciência e Tecnologia (FCT) (http://www.fct.pt), Portugal. Claudia Palladino is supported by the Portuguese Fundação para a Ciência e Tecnologia (FCT) (SFRH/BPD/77448/2011). Verónica Briz is supported by the Spanish Fondo de Investigación Sanitaria (Sara Borrell CD09/00433. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.